Bivalent thrombin inhibitors
CA 2175388 A1 · Owner: National Research Council Of Canada · Inventors: Konishi, Yasuo; Tsuda, Yuko; Szewczuk, Zbigniew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Hirudin is the most potent and specific thrombin inhibitor and is derived from the medicinal leech. It is reported to inhibit thrombin with an equilibrium dissociation constant (Ki) value of 2.2 x 10-14 M. synthetic thrombin inhibitors have been designed based on the hirudin sequence but with a dramatically reduced size. The bulky active site inhibitor segment hirudin1-, 48, has been substituted by small non-substrate type active site inhibitors of thrombin, e.g. dansyl-Arg-(D-pipecolic acid). The linker segment has also been modified using a combination of .omega.-amino acids to reduce the molecular weight but retaining sufficient length to span the two principal binding domains. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 25, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 25, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 25, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.